Factor VIII biosimilar - Amega Biotech

Drug Profile

Factor VIII biosimilar - Amega Biotech

Alternative Names: Recombinant factor VIII - Amega Biotech

Latest Information Update: 15 Aug 2013

Price : $50

At a glance

  • Originator Amega Biotech
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Haemophilia B

Most Recent Events

  • 15 Aug 2013 Investigation in Haemophilia B in Argentina (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top